Madrigal Pharmaceuticals, Inc. Share Price
Equities
MDGL
US5588681057
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
193.3 USD | -0.54% | -8.82% | -16.44% |
Sales 2024 * | 81.74M 6.54B | Sales 2025 * | 351M 28.14B | Capitalization | 4.06B 325B |
---|---|---|---|---|---|
Net income 2024 * | -459M -36.74B | Net income 2025 * | -296M -23.7B | EV / Sales 2024 * | 48.5 x |
Net cash position 2024 * | 93.53M 7.49B | Net Debt 2025 * | 116M 9.31B | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
-8.3
x | P/E ratio 2025 * |
-13
x | Employees | 376 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.04% |
Latest transcript on Madrigal Pharmaceuticals, Inc.
1 day | -0.54% | ||
1 week | -8.82% | ||
Current month | -27.60% | ||
1 month | -25.30% | ||
3 months | -14.44% | ||
6 months | +60.57% | ||
Current year | -16.44% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 31/08/11 |
William Sibold
CEO | Chief Executive Officer | - | 07/09/23 |
Rebecca Taub
FOU | Founder | 71 | 30/06/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 31/08/11 | |
Julian Baker
CHM | Chairman | 57 | 14/06/23 |
Ken Bate
BRD | Director/Board Member | 73 | 21/07/16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 193.3 | -0.54% | 453,346 |
25/04/24 | 194.4 | -5.02% | 707,188 |
24/04/24 | 204.6 | -6.29% | 575,504 |
23/04/24 | 218.4 | +2.29% | 409,554 |
22/04/24 | 213.5 | +0.68% | 727,326 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.44% | 4.06B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MDGL Stock